Overview

Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics and pharmacodynamics of single escalating doses of PF-05231023.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer